Karyopharm extends indenture forbearance period to Oct 22, 2026 from Oct 15

Karyopharm Therapeutics Inc.

Company extended the end of its Forbearance Period from 11:59 p.m. ET Oct 15, 2026 to 11:59 p.m. ET Oct 22, 2026, absent earlier termination.
Extension made under Section 19 of the Forbearance Agreement and Limited Waiver to Indentures dated Sept 10, 2026, disclosed in a Sept 11, 2026 Form 8-K.
Filing does not specify note principal amounts, interest rates, or the underlying covenant defaults prompting forbearance.
Signed Oct 14, 2026 by Michael Mano, Executive Vice President, Chief Legal Officer and Secretary; KPTI trades on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.